CS-1008

DRUG5 trials

Sponsors

Daiichi Sankyo, Ludwig Institute for Cancer Research

Conditions

Colorectal NeoplasmsMetastatic Colorectal CancerNon-small Cell Lung CancerOvarian Cancer Stage IIICOvarian Cancer Stage IV

Phase 1

Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

CompletedNCT01124630

Daiichi SankyoMetastatic Colorectal Cancer

Start: 2010-05-31End: 2013-08-31Updated: 2013-12-03

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

CompletedNCT01220999

Ludwig Institute for Cancer ResearchColorectal Neoplasms

Start: 2010-10-12End: 2012-06-27Updated: 2022-10-28

Phase 2

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

CompletedNCT00945191

Daiichi SankyoOvarian Cancer Stage IIIC, Ovarian Cancer Stage IV

Start: 2009-10-06End: 2011-08-23Updated: 2021-04-08

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

TerminatedNCT00969033

Daiichi SankyoMetastatic Colorectal Cancer

Start: 2009-07-31End: 2011-12-31Updated: 2012-01-31

CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)

CompletedNCT00991796

Daiichi SankyoNon-small Cell Lung Cancer

Start: 2009-06-30End: 2011-12-31Updated: 2012-09-10